RxDoctor Payments Data

Lucia Tuffanelli, MD

Dermatology · San Francisco, CANPI 1760474894

Payments from drug & device makers

$33,526in general payments, 2019–2025

Across 1,120 payments — averaging $29.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11K
  • AbbVie$4K
  • Sun Pharmaceutical Industries Inc.$3K
  • Johnson & Johnson$2K
  • Lilly USA, LLC$2K
  • LEO Pharma Inc.$1K
  • plus $10K from 35 others

What the payments were for

  • Consulting fees$2,8008%
  • Speaking & faculty fees$8,60026%
  • Food & beverage$21,73165%
  • Education$3951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,526 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$262,298
Medicare patients
811
Services billed
3,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab37$139,348
OpzeluraRuxolitinib Phosphate15$27,615
OraceaDoxycycline Monohydrate15$13,060
Azelaic Acid99$10,528
Tacrolimus30$8,161
Fluocinonide114$6,858
Clobetasol Propionate127$5,474
CiclopiroxCiclopirox Olamine104$5,248
Calcipotriene20$4,500
Ketoconazole246$4,165
Triamcinolone Acetonide252$2,885
Metronidazole41$2,343
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc105$2,141
Clindamycin Phosphate59$2,107
Fluorouracil37$1,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$713$27,61515 claims
Galderma Laboratories, L.p.Oracea$1,163$13,06015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,875 dermatology providers in California.

Other dermatology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →